Molecule Information

General Information of the Molecule (ID: Mol01226)

Name	Solute carrier family 6 member 9 (SLC6A9) ,Homo sapiens
Synonyms	SLC6A9 Click to Show/Hide
Molecule Type	LncRNA
Gene Name	C6orf218, MGC40222
Gene ID	6536
Location	chr1:43991500-44031467[-]
Ensembl ID	ENSG00000196517
HGNC ID	HGNC:11056
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Investigative Drug(s)

1 drug(s) in total

Click to Show/Hide the Full List of Drugs

Iodine-131

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Epigenetic Alteration of DNA, RNA or Protein (EADR)			Click to Show/Hide
Disease Class: Papillary thyroid carcinoma				[1]
Resistant Disease	Papillary thyroid carcinoma [ICD-11: 2D10.1]			Disease Info
Resistant Drug	Iodine-131			Drug Info
Molecule Alteration	Expression		Down-regulation
Experimental Note	Identified from the Human Clinical Data
Cell Pathway Regulation	SLC6A9/PARP1 signaling pathway		Inhibition	hsa04064
In Vitro Model	BCPAP cells	Thyroid	Homo sapiens (Human)	CVCL_0153
	TPC-1 cells	Thyroid	Homo sapiens (Human)	CVCL_6298
Experiment for Molecule Alteration	qRT-PCR
Experiment for Drug Resistance	MTT assay
Mechanism Description	SLC6A9-5:2 overexpression was positively correlated with PARP-1 mRNA and protein levels, which restored the sensitivity of resistant thyroid cancer cells. SLC6A9 is positively correlated with PARP-1 expression, and PARP-1 inhibition makes thyroid cancer cells resistant to 131I. Upregulation of the SLC6A9-PARP-1 pathway enhanced the sensitivity to 131I treatment through energy exhaustion during excess RNA repair.

Disease- and Tissue-specific Abundances of This Molecule

ICD Disease Classification 02

Click to Show/Hide the Resistance Disease of This Class

Thyroid cancer [ICD-11: 2D10]

Click to Show/Hide

Differential expression of molecule in resistant diseases
The Studied Tissue	Thyroid
The Specified Disease	Thyroid carcinoma
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.85E-44; Fold-change: 1.62E-01
Molecule expression in the diseased tissue of patients Molecule expression in the normal tissue of healthy individuals
Disease-specific Molecule Abundances		Click to View the Clearer Original Diagram
Download Molecule expression barchart for all samples Download Molecule expression data of patients in the disease section of the tissue Download Molecule expression data in the tissue of healthy individual

Tissue-specific Molecule Abundances in Healthy Individuals

Click to Show/Hide the Molecule Abundances


Download the Tissue-Specific Variation(s) Profile

References

Ref 1	LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction. Oncotarget. 2017 Apr 4;8(14):22954-22967. doi: 10.18632/oncotarget.14578.